Quantx Biosciences closed an $85 million Series B to finance IND-enabling work and early clinical trials for two oral immunology candidates: a STAT6 inhibitor and an IL‑17 inhibitor. The raise, described as oversubscribed, funds Quantx’s plan to start first-in-human studies and to expand preclinical work on its computational discovery platform. Investors backing oral small-molecule alternatives to biologics are betting on differentiated convenience and manufacturing economics for chronic immunologic diseases. Quantx says its physics-based and statistical modeling approach accelerates hit-to-lead timelines for oral molecules targeting traditionally hard-to-drug pathways.